Psychopharmacoendocrinology and Depression Research

1 Introduction.- 1.1 Outline of the Study.- 1.2 Effect of Psychotropic Drugs on Central Nervous Aminergic Stimuli Transmission.- 1.3 Influence of Aminergic Neuronal Systems on Anterior Pituitary Hormone Secretion.- 1.4 Aminergic Neurons, APH Secretion and Depression Research.- 2 Influence of Psychotropic Drugs on Anterior Pituitary Hormone Secretion in Healthy Subjects.- 2.1 Healthy Subjects and Methods.- 2.2 Influence of Psychotropic Drugs on GH Secretion.- 2.2.1 Antidepressants and GH Secretion.- 2.2.1.1 Desipramine.- 2.2.1.2 Clomipramine.- 2.2.1.3 Nomifensine.- 2.2.1.4 L- and D-Oxaprotiline.- 2.2.1.5 Bupropion.- 2.2.1.6 Indalpine.- 2.2.1.7 Summary.- 2.2.2 Neuroleptics and GH Secretion.- 2.2.2.1 Haloperidol.- 2.2.2.2 Summary.- 2.2.3 Benzodiazepine Derivatives and GH Secretion.- 2.2.3.1 Diazepam and Metaclazepam.- 2.2.3.2 Summary.- 2.2.4 Discussion.- 2.3 Influence of Psychotropic Drugs on Prolactin Secretion.- 2.3.1 Antidepressants and PRL Secretion.- 2.3.1.1 Desipramine.- 2.3.1.2 Clomipramine.- 2.3.1.3 Nomifensine.- 2.3.1.4 L- and D-Oxaprotiline.- 2.3.1.5 Bupropion.- 2.3.1.6 Indalpine.- 2.3.1.7 Summary.- 2.3.2 Neuroleptics and PRL Secretion.- 2.3.2.1 Haloperidol.- 2.3.2.2 Summary.- 2.3.3 Benzodiazepine Derivatives and PRL Secretion.- 2.3.3.1 Diazepam.- 2.3.3.2 Summary.- 2.3.4 Discussion.- 2.4 Influence of Psychotropic Drugs on Cortisol/ACTH Secretion.- 2.4.1 Antidepressants and Cortisol/ACTH Secretion.- 2.4.1.1 Desipramine.- 2.4.1.2 Clomipramine.- 2.4.1.3 L- and D-Oxaprotiline.- 2.4.1.4 Indalpine.- 2.4.1.5 Summary.- 2.4.2 Neuroleptics and Cortisol Secretion.- 2.4.2.1 Sulpiride.- 2.4.2.2 Summary.- 2.4.3 Benzodiazepine Derivatives and Cortisol/ACTH Secretion.- 2.4.3.1 Diazepam.- 2.4.3.2 Summary.- 2.4.4 Discussion.- 2.5 Discussion.- 3 Influence of Receptor Blockers and Receptor Agonists on Antidepressant-Induced Anterior Pituitary Hormone Secretion in Healthy Subjects.- 3.1 Healthy Subjects and Methods.- 3.2 Influence of Receptor Blockers and Receptor Agonists on DMI-Induced GH Stimulation.- 3.2.1 GH, DMI, and Methysergide.- 3.2.2 GH, DMI, and Phentolamine.- 3.2.3 GH, DMI, and Yohimbin.- 3.2.4 GH, DMI, and Prazosin.- 3.2.5 GH, DMI, and Propranolol.- 3.2.6 GH, DMI, and Clenbuterol.- 3.2.6 Summary.- 3.3 Influence of Receptor Blockers and Receptor Agonists on DMI-Induced PRL Stimulation.- 3.3.1 PRL, DMI, and Methysergide.- 3.3.2 PRL, DMI, and Phentolamine.- 3.3.3 PRL, DMI, and Yohimbin.- 3.3.4 PRL, DMI, and Prazosin.- 3.3.5 PRL, DMI, and Propranolol.- 3.3.6 PRL, DMI, and Clenbuterol.- 3.3.7 Summary.- 3.4 Influence of Receptor Blockers and Receptor Agonists on DMI-Induced Cortisol/ACTH Stimulation.- 3.4.1 Cortisol, DMI, and Methysergide.- 3.4.2 Cortisol, DMI, and Phentolamine.- 3.4.3 Cortisol, DMI, and Yohimbin.- 3.4.4 Cortisol, ACTH, DMI, and Prazosin.- 3.4.5 Cortisol, DMI, and Propranolol.- 3.4.6 Cortisol, DMI, and Clenbuterol.- 3.4.7 Summary.- 3.5 Discussion.- 4 Desipramine-Induced Growth Hormone Stimulation in Depressive Patients and Healthy Subjects.- 4.1 GH Secretion after Desipramine in Depressive Patients and Healthy Subjects.- 4.2 Healthy Subjects, Patients, and Methods.- 4.2.1 GH Secretion after DMI in Male and Female Healthy Subjects of Differing Age.- 4.2.2 Case Records of the Patients.- 4.2.3 Selection of the Patients.- 4.2.4 Evaluation of the Trial Group.- 4.3 Results.- 4.3.1 Healthy Male and Female Subjects.- 4.3.1.1 GH Secretion after DMI in Healthy Male Subjects Grouped According to Their Age in Decades.- 4.3.1.2 GH Secretion after DMI in Healthy Female Subjects Grouped According to Their Age in Decades.- 4.3.1.3 GH Secretion after DMI in Healthy Female Subjects in Relationship to the Menstrual Cycle.- 4.3.1.4 Summary.- 4.3.2 GH Secretion after Administration of DMI in Male and Female Patients.- 4.3.2.1 Severity of the Depressive Disease (Hamilton Depression Scale) and GH Secretion.- 4.3.2.2 GH Secretion after DMI in Depressive Patients (Grouped According to Diagnosis) in Comparison with Healthy Subjects.- 4.3.2.2.1 Monopolar Endogenous Depressive Male Patients (ICD 296.1).- 4.3.2.2.2 Bipolar Endogenous Depressive Male Patients (ICD 296.3).- 4.3.2.2.3 Neurotic Depressive Male Patients (ICD 300.4).- 4.3.2.2.4 Monopolar Endogenous Depressive Female Patients (ICD 296.1).- 4.3.2.2.5 Bipolar Endogenous Depressive Female Patients (ICD 296.3).- 4.3.2.2.6 Neurotic Depressive Female Patients (ICD 300.4).- 4.3.2.3 Summary.- 4.3.3 Group Comparison of GH Secretion after DMI and DMI-Induced GH Stimulation in Patients and Healthy Subjects.- 4.3.3.1 GH Secretion Reflected in the AUCs after DMI in Male Patients and in Healthy Male Subjects.- 4.3.3.2 GH Secretion Reflected in the AUCs after DMI in Female Patients and Healthy Female Subjects.- 4.3.3.3 GH Stimulation 60 min after DMI in Male Patients in Comparison with Healthy Male Subjects.- 4.3.3.4 GH Stimulation 60 min after DMI in Female Patients in Comparison with Healthy Female Subjects.- 4.4 Summary and Discussion.- 5 Summary.- 6 Reference.